Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug name review

Executive Summary

FDA drug name review should be based on data collected from sponsors, rather than from internal agency tests, HHS Advisory Committee on Regulatory Reform recommends during Sept. 9 teleconference. FDA is developing three guidances to help avoid medication errors caused by drug name confusion: to define policy on submitting trade names; provide labeling recommendations; and provide specifics on analysis and submission of data for review (1"The Pink Sheet" Sept. 10, 2001, p. 32)...

You may also be interested in...



Rx Name Risk Assessments Should Be Conducted By Manufacturers, FDA Says

Drug and biologic sponsors should conduct a risk assessment on the product's name, labeling and packaging to minimize medication errors, an FDA concept paper states

Drug name guidances

FDA is working on three guidances to help avoid medication errors due to drug name confusion. The first addresses policy considerations related to the process of submitting trade names, such as what FDA will and will not accept; another guidance provides general recommendations on labeling and packaging issues, including prominence and total drug content; the third will provide more specifics on the analysis and submission of data for trade name review, including possible studies companies could conduct to evaluate look-alike and sound-alike names

Bluebird’s Zynteglo Approval Kicks Off Commercial Operations

Bluebird bio’s Tom Klima told Scrip launch preparations are well under way, including negotiations with payers on outcomes-based reimbursement agreements.

Latest News
See All
UsernamePublicRestriction

Register

PS040464

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel